Cutaneous and Ganglion Sarcoidosis Induced by Polycaprolactone Facial Filler: A New Expression of ASIA Syndrome?
  • Juan Ortiz-Álvarez
    UGC de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  • Jose Antonio Lebron-Martin
    UGC de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  • Lourdes Rodriguez Fernandez-Freire
    UGC de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  • Teresa Zulueta-Dorado
    UGC de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  • Jose Salvador Garcia-Morillo
    Unidad de Enfermedades Raras y Autoinmunes del Adulto, UGC Medicina Integral, Hospital Universitario Virgen del Rocío, Sevilla, Spain

Keywords

Polycaprolactone filler, sarcoidosis, ASIA syndrome

Abstract

Dermal fillers are applied using a minimally invasive technique with a good safety profile. However, they can have side effects. We present the case of a patient who, 2 months after undergoing polycaprolactone (Ellansé®) injections, developed nodular facial and nodal lesions that were compatible with sarcoidosis on histology. This complication has not been previously described for polycaprolactone and could be the expression of an autoimmune syndrome induced by adjuvants.

VIEW THE ENTIRE ARTICLE

References

  • SWanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med 2015;36(4):685–702. Available from: http://dx.doi.org/10.1016/j.ccm.2015.08.010
  • Levy L, Emer J. Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg 2012;5(2):121–132.
  • Lin SL, Christen MO. Polycaprolactone-based dermal filler complications: a retrospective study of 1111 treatments. J Cosmet Dermatol 2020;19(8):1907–1914.
  • Sommerfeld S, Cherry C, Schwab R, Chung L, Maestas DJ, Laffont P, et al. Interleukin-36?–producing macrophages drive IL-17–mediated fibrosis. Sci Immunol 2019;11(4):eaax4783.
  • Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria.Lupus 2015;24(10):1012–1018.
  • Views: 681
    HTML downloads: 444
    PDF downloads: 389


    Published: 2021-06-09
    Issue: 2021: Vol 8 No 6 (view)


    How to cite:
    1.
    Ortiz-Álvarez J, Lebron-Martin JA, Rodriguez Fernandez-Freire L, Zulueta-Dorado T, Garcia-Morillo JS. Cutaneous and Ganglion Sarcoidosis Induced by Polycaprolactone Facial Filler: A New Expression of ASIA Syndrome?. EJCRIM 2021;8 doi:10.12890/2021_002652.